JP2014529403A5 - - Google Patents

Download PDF

Info

Publication number
JP2014529403A5
JP2014529403A5 JP2014526493A JP2014526493A JP2014529403A5 JP 2014529403 A5 JP2014529403 A5 JP 2014529403A5 JP 2014526493 A JP2014526493 A JP 2014526493A JP 2014526493 A JP2014526493 A JP 2014526493A JP 2014529403 A5 JP2014529403 A5 JP 2014529403A5
Authority
JP
Japan
Prior art keywords
core
microorganism
positive
antigen expression
lysate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014526493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014529403A (ja
JP6148671B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/066360 external-priority patent/WO2013026887A1/en
Publication of JP2014529403A publication Critical patent/JP2014529403A/ja
Publication of JP2014529403A5 publication Critical patent/JP2014529403A5/ja
Application granted granted Critical
Publication of JP6148671B2 publication Critical patent/JP6148671B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014526493A 2011-08-22 2012-08-22 腫瘍抗原を保有する微生物 Expired - Fee Related JP6148671B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161526054P 2011-08-22 2011-08-22
US61/526,054 2011-08-22
EP11178322.1 2011-08-22
EP11178322 2011-08-22
PCT/EP2012/066360 WO2013026887A1 (en) 2011-08-22 2012-08-22 Microorganisms carrying a tumor antigen

Publications (3)

Publication Number Publication Date
JP2014529403A JP2014529403A (ja) 2014-11-13
JP2014529403A5 true JP2014529403A5 (enrdf_load_stackoverflow) 2015-10-01
JP6148671B2 JP6148671B2 (ja) 2017-06-14

Family

ID=47745974

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014526493A Expired - Fee Related JP6148671B2 (ja) 2011-08-22 2012-08-22 腫瘍抗原を保有する微生物

Country Status (11)

Country Link
US (1) US9700610B2 (enrdf_load_stackoverflow)
EP (1) EP2748302B1 (enrdf_load_stackoverflow)
JP (1) JP6148671B2 (enrdf_load_stackoverflow)
CN (1) CN103814123A (enrdf_load_stackoverflow)
AU (1) AU2012298496A1 (enrdf_load_stackoverflow)
BR (1) BR112014004065A2 (enrdf_load_stackoverflow)
CA (1) CA2844543A1 (enrdf_load_stackoverflow)
ES (1) ES2686313T3 (enrdf_load_stackoverflow)
IL (1) IL231065A0 (enrdf_load_stackoverflow)
RU (1) RU2014110953A (enrdf_load_stackoverflow)
WO (1) WO2013026887A1 (enrdf_load_stackoverflow)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1920781B1 (en) * 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
CN103814123A (zh) 2011-08-22 2014-05-21 葛莱高托普有限公司 携带肿瘤抗原的微生物
JP6212538B2 (ja) * 2013-12-20 2017-10-11 株式会社ダイセル 脂質代謝改善作用を有する栄養組成物

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4931275A (en) 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
WO1992015682A1 (en) 1991-02-27 1992-09-17 Creative Biomolecules, Inc. Serine-rich peptide linkers
EP0636029B1 (en) 1992-04-13 2000-11-08 Dana-Farber Cancer Institute, Inc. Antibodies specific for carcinoma-associated antigens
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
EP0702722B1 (en) 1993-06-07 2005-08-03 Vical Incorporated Plasmids suitable for gene therapy
DE4329004A1 (de) 1993-08-28 1995-03-09 Max Delbrueck Centrum Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis
US7137011B1 (en) 1993-09-01 2006-11-14 Sandisk Corporation Removable mother/daughter peripheral card
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
EP0833907A1 (en) 1995-06-23 1998-04-08 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1997040182A1 (de) 1996-04-19 1997-10-30 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
EP1032428B1 (en) 1997-11-20 2003-06-18 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
AUPP816899A0 (en) 1999-01-14 1999-02-11 Food Technology Innovations Pty Limited Improved microbial products
AU3508300A (en) 1999-03-02 2000-09-21 Human Genome Sciences, Inc. Engineering intracellular sialylation pathways
EP1167537B1 (en) 1999-03-30 2008-07-23 Japan Tobacco Inc. Process for producing monoclonal antibody
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
DE60018761T2 (de) 1999-08-18 2006-02-02 Altarex Medical Corp., Edmonton Therapeutischer antikörper gegen das muc-1-antigen und verfahren zu dessen verwendung
AU7743100A (en) 1999-09-30 2001-04-30 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
FR2809312B1 (fr) 2000-05-25 2002-07-12 Gervais Danone Sa Utilisation de l. casei dans des compositions immunostimulantes
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
KR100866199B1 (ko) 2001-02-01 2008-10-30 가부시끼가이샤 야구르트혼샤 발효유 음식품 중의 비피도박테리움속 세균의 장내 도달도평가방법
DE10139428A1 (de) 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
WO2003016329A2 (en) 2001-08-17 2003-02-27 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Glycoconjugates of sialic acid derivates, methods for their production and use thereof
US20040115177A1 (en) 2001-10-12 2004-06-17 Harris Delbert L. Probiotic compositions and methods against bacterial infection in livestock animals
GB0125473D0 (en) 2001-10-24 2001-12-12 Syngenta Ltd Chemical process
JP2005517389A (ja) 2001-11-20 2005-06-16 アトゲン カンパニー リミティッド 環境ストレス耐性を有する新規のペプチド及びこれを含む融合蛋白質
EP1529060B1 (de) 2002-07-22 2014-09-10 Glycotope GmbH Verfahren zur herstellung eines immunstimulatorischen muzins (muc1)
WO2004018659A1 (en) 2002-08-16 2004-03-04 Glycotope Gmbh Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
US8887358B2 (en) * 2003-02-14 2014-11-18 Christie Marie Cox Burial vault carapace and method for customizing a burial vault carapace
GB0315991D0 (en) 2003-07-08 2003-08-13 Dakocytomation Denmark As Standard
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ES2425475T3 (es) * 2003-08-18 2013-10-15 Glycotope Gmbh Líneas de células tumorales NM-F9 (DSM ACC2606) y NM-D4 (DSM ACC2605), usos de las mismas
FR2861080B1 (fr) 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
WO2005080585A1 (en) 2004-02-13 2005-09-01 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
EP1789027B1 (en) 2004-07-26 2013-09-04 The Research Foundation Of State University Of New York Therapeutic use of anti-tf-antigen antibody
US7598134B2 (en) 2004-07-28 2009-10-06 Micron Technology, Inc. Memory device forming methods
WO2007041495A2 (en) * 2005-09-29 2007-04-12 University Of California, San Diego Dampening humoral and innate immunity by inhibition of ppgalnact-1
WO2007120932A2 (en) * 2006-04-19 2007-10-25 Neose Technologies, Inc. Expression of o-glycosylated therapeutic proteins in prokaryotic microorganisms
WO2007124992A1 (en) 2006-04-28 2007-11-08 Unilever N.V. Method of manufacturing a cultured edible product comprising omega-3 polyunsaturated fatty acids
EP2428223A3 (en) 2006-09-10 2012-05-16 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
EP1920781B1 (en) 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
AR063868A1 (es) * 2007-11-20 2009-02-25 Tecn Conicet Consejo Nac De In Inmunogeno modificado del disacarido de thomsen- friedenreich (tfd) procedimiento de elaboracion, composiciones que lo contine, usos y metodos de tratamiento
US20090324617A1 (en) * 2008-01-24 2009-12-31 Glykos Finland Ltd. Cancer specific glycans and use thereof
JP2011520435A (ja) * 2008-05-13 2011-07-21 グリコトープ ゲーエムベーハー 発酵プロセス
US8784293B2 (en) 2008-10-07 2014-07-22 Advanced Brain Monitoring, Inc. Systems and methods for optimization of sleep and post-sleep performance
CN101560488A (zh) 2009-05-27 2009-10-21 中国农业大学 分解木质纤维素的酶与菌剂
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US20110076356A1 (en) * 2009-09-29 2011-03-31 Ziemer Cherie J Novel Fibro-Biotic Bacterium Isolate
GB2475226A (en) * 2009-11-03 2011-05-18 Genetic Analysis As Universal Prokaryote 16S ribosome PCR primer pair
US8795746B2 (en) * 2011-02-16 2014-08-05 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic use of mucin glycans
US8951762B2 (en) * 2011-07-27 2015-02-10 Iowa State University Research Foundation, Inc. Materials and methods for using an acyl—acyl carrier protein thioesterase and mutants and chimeras thereof in fatty acid synthesis
CN103814123A (zh) 2011-08-22 2014-05-21 葛莱高托普有限公司 携带肿瘤抗原的微生物
US9868957B2 (en) * 2012-08-07 2018-01-16 TopGeniX, Inc. Topical composition comprising transformed bacteria expressing a compound of interest
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9518872B2 (en) 2014-10-14 2016-12-13 Kidde Technologies, Inc. Thermal sensor

Similar Documents

Publication Publication Date Title
JP2019515646A5 (enrdf_load_stackoverflow)
JP2020023523A5 (enrdf_load_stackoverflow)
JP2007530435A5 (enrdf_load_stackoverflow)
PE20181952A1 (es) Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos
JP2020526214A5 (enrdf_load_stackoverflow)
CO2018004532A2 (es) Anticuerpos anti-cd19 humano con alta afinidad
JP2021501744A5 (enrdf_load_stackoverflow)
CA2699834A1 (en) Improved anti-il-6 receptor antibody
JP2020500508A5 (enrdf_load_stackoverflow)
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
JP2012500020A5 (enrdf_load_stackoverflow)
JP2019506155A5 (enrdf_load_stackoverflow)
JP2012524524A5 (enrdf_load_stackoverflow)
JP2020537520A5 (enrdf_load_stackoverflow)
NZ600622A (en) Compositions and methods for antibodies targeting complement protein c5
WO2018091740A3 (en) Novel anti_cd137 antibodies and uses thereof
RU2011110169A (ru) Антитела против ccr2
JP2016511750A5 (enrdf_load_stackoverflow)
CL2008003004A1 (es) Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos.
JP2010022372A5 (enrdf_load_stackoverflow)
WO2010037838A3 (en) Cross-species-specific single domain bispecific single chain antibody
JP2012518425A5 (enrdf_load_stackoverflow)
JP2014518883A5 (enrdf_load_stackoverflow)
JP2019522961A5 (enrdf_load_stackoverflow)
JP2017534259A5 (enrdf_load_stackoverflow)